Anbogen’s Core Team Wins at Stanford Global Kaggle Competition, Demonstrating the Strength of Its AI Drug Discovery Engine
Anbogen Therapeutics today announced that its core team, led by CEO Dr. Tsu-An Hsu, stood out from 1,485 teams worldwide and won the silver medal at the prestigious Stanford University–hosted Kaggle global competition. This accomplishment is more than a single victory; it represents a rigorous “stress test” and authoritative validation of the company’s AI drug discovery engine.
This year’s competition, themed RNA 3D Structure Prediction, addresses a critical bottleneck in modern drug development. Anbogen’s exceptional performance demonstrated that its AI platform has mastered advanced technologies for analyzing both protein and RNA targets, laying a solid foundation for the company’s future strategy to tackle so-called “undruggable targets.”
“We believe in letting actions speak louder than words,” said Dr. Hsu. “This achievement reflects our long-term investment in AI R&D. What it shows to partners and investors is not simply that we won a competition, but that we have built a research engine capable of truly solving problems. This validated capability will be our strongest support when we announce concrete progress in our drug pipeline.”
Building on this proven R&D engine, Anbogen will continue to transform its advanced computational power into tangible preclinical drug assets, driving sustained efforts toward meaningful breakthroughs in future development programs.
This year’s competition, themed RNA 3D Structure Prediction, addresses a critical bottleneck in modern drug development. Anbogen’s exceptional performance demonstrated that its AI platform has mastered advanced technologies for analyzing both protein and RNA targets, laying a solid foundation for the company’s future strategy to tackle so-called “undruggable targets.”
“We believe in letting actions speak louder than words,” said Dr. Hsu. “This achievement reflects our long-term investment in AI R&D. What it shows to partners and investors is not simply that we won a competition, but that we have built a research engine capable of truly solving problems. This validated capability will be our strongest support when we announce concrete progress in our drug pipeline.”
Building on this proven R&D engine, Anbogen will continue to transform its advanced computational power into tangible preclinical drug assets, driving sustained efforts toward meaningful breakthroughs in future development programs.